H6D.STU Haleon PLC

Healthcare Pharmaceuticals Stuttgart Exchange
8.44 EUR
Close of Oct 31, 2026
7.20 9.36
Market cap
EUR 38.9B
P/E
18.1x
P/B
1.97x
ROE
10.1%
Dividend yield
1.36%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is H6D.STU undervalued?

Graham number
Price8.44
Graham value6.71
Premium25.7%

H6D.STU trades 25.7% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Haleon PLC fundamental analysis

No fundamental analysis for Haleon PLC yet.

Haleon PLC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Haleon PLC

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, an…

Full company profile